Hyperthyroidism

Endocrinology and Metabolism Clinics of North America

Volumn 36, Issue 3, 2007, Pages 617-656

  Nayak, Bindu ^a,b   Hodak, Steven P ^c  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOBETASOL PROPIONATE; COLESTYRAMINE; DUODERM; FLUOCINOLONE ACETONIDE; FOLLITROPIN; GLUCOCORTICOID; GONADORELIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; IODINE; IODINE 123; IODINE 131; LIOTHYRONINE; LITHIUM; LUTEINIZING HORMONE; OSTEOCLAST DIFFERENTIATION FACTOR; PERTECHNETIC ACID TC 99M; POTASSIUM PERCHLORATE; RADIOACTIVE IODINE; STEROID; TECHNETIUM 99M; THIONAMIDE DERIVATIVE; THYROID HORMONE; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE; UNINDEXED DRUG;

AGRANULOCYTOSIS; APLASTIC ANEMIA; ARTHRALGIA; ARTHRITIS; AUTOIMMUNE THYROIDITIS; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DRUG FATALITY; DRUG WITHDRAWAL; ECHOGRAPHY; FEVER; GASTRITIS; GRAVES DISEASE; HEMOPTYSIS; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; KIDNEY FAILURE; LIVER TOXICITY; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SECOND CANCER; SIALOADENITIS; SINUSITIS; SKIN MANIFESTATION; SKIN ULCER; SORE THROAT; TASTE DISORDER; THYROID ADENOMA; THYROID FUNCTION TEST; THYROID HORMONE BLOOD LEVEL; THYROID SCINTISCANNING; THYROID SURGERY; THYROIDITIS; THYROTOXICOSIS; TOXIC GOITER; URTICARIA; VASCULITIS; VIRUS INFECTION;

ANTITHYROID AGENTS; DIAGNOSTIC IMAGING; FEMALE; GOITER; GRAVES DISEASE; HUMANS; HYPERTHYROIDISM; LABORATORY TECHNIQUES AND PROCEDURES; PREGNANCY; PREGNANCY COMPLICATIONS; THYROID FUNCTION TESTS; THYROID NEOPLASMS; THYROIDITIS; THYROTOXICOSIS;

EID: 34547260389     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2007.06.002     Document Type: Review

References (169)

1. Larsen P.R., Davies T.F., et al. Thyrotoxicosis. In: Larsen P.R., Kronenberg H.M., Melmed S., et al. (Eds). Williams' textbook of endocrinology. 10th edition (2002), WB Saunders Co, Philadelphia 374-421
2. Turnbridge W.M.G., Evered D.C., and Hall R. The spectrum of thyroid disease in a community. Clin Endocrinol (Oxf) 7 (1977) 483-493
3. Takasu N., Yamada T., Sato A., et al. Graves' disease following hyperthyroidism due to Hashimoto's disease: studies of eight cases. Clin Endocrinol (Oxf) 33 6 (1990) 687-698
4. Marcocci C., Bartalena L., Bogazzi F., et al. Studies on the occurrence of ophthalmopathy in Graves' disease. Acta Endocrinol (Copenh) 120 4 (1989) 473-478
5. Fatourechi V. Pretibial myxedema: pathophysiology and treatment options. Am J Clin Dermatol 6 5 (2005) 295-309
6. Bahn R.S. Understanding the immunology of Graves' ophthalmopathy: is it an autoimmune disease?. Endocrinol Metab Clin North Am 29 (2000) 287-296
7. Salvi M., Zhang Z.-G., and Haegert D. Patients with endocrine ophthalmopathy not associated with overt thyroid disease have multiple thyroid immunological abnormalities. J Clin Endocrinol Metab 70 (1990) 89-94
8. Prabhakar B., Bahn R.S., and Smith T.J. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev 24 6 (2003) 802-835
9. Smith T.J. Dexamethasone regulation of glycosaminoglycan synthesis cultured human fibroblasts: similar effects of glucocorticoid and thyroid hormone therapy. J Clin Invest 64 (1984) 2157-2163
10. Dabon-Almirante C.L., and Surks M. Clinical and laboratory diagnosis of thyrotoxicosis. Endocrinol Metab Clin North Am 27 1 (1998) 25-35
11. Bull R.H., Coburn P.R., and Mortimer P.S. Pretibial myxedema: a manifestation of lymphoedema?. Lancet 341 (1993) 403-404
12. Kriss J.P., Pleshakov V., Rosenblum A., et al. Therapy with occlusive dressings of pretibial myxedema with fluocinolone acetonide. J Clin Endocrinol Metab 27 (1967) 595-604
13. Volden G. Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing. Acta Derm Venereol 72 (1992) 69-71
14. Schwartz K.M., Fatourechi V., Ahmed D., et al. Dermopathy of Graves' disease (pretibial myxedema). J Clin Endocrinol Metab 87 2 (2002) 438-446
15. Jabbour S.A. Cutaneous manifestations of endocrine disorders. Am J Clin Dermatol 4 5 (2003) 315-331
16. Tonacchera M., Agretti P., Chiovato L., et al. Activating thyrotropin receptor mutations are present in nonadenomatous hyperfunctioning nodules of toxic or autonomous multinodular goiter. J Clin Endocrinol Metab 85 (2000) 2270-2274
17. Tonacchera M., VanSande J., Cetani F., et al. Functional characteristics of three new germline mutations of the thyrotropin receptor gene causing autosomal dominant toxic thyroid hyperplasia. J Clin Endocrinol Metab 81 (1996) 547-554
18. Fatourechi V., Aniszewski J.P., Jacobsen S.J., et al. Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmstead County, Minnesota, study. J Clin Endocrinol Metab 88 5 (2003) 2100-2105
19. Weetman A.P., Smallridge R.C., Nutman T.B., et al. Persistent thyroid autoimmunity after subacute thyroiditis. J Clin Lab Immunol 23 (1987) 1-6
20. Stancek D., Stancekova-Gressnerova M., Janotka M., et al. Isolation and some serological and epidemiological data on the viruses recovered from patients with subacute thyroiditis de Quervain. Med Microbiol Immunol 161 (1975) 133-144
21. Martino E., Buratti L., Bartalena L., et al. High prevalence of subacute thyroiditis during summer season in Italy. J Endocrinol Invest 10 (1987) 321-323
22. Farwell A.P. Subacute thyroiditis and acute infectious thyroiditis. In: Braverman L.E., and Utiger R.D. (Eds). Werner's and Ingbar's the thyroid. 9th edition (2005), Lipincott, Williams, Wilkins, Philadelphia 536-547
23. Pearce E.N., Farwell A.P., and Braverman L.E. Thyroiditis. N Engl J Med 348 26 (2003) 2646-2655
24. Lio S., Pontecorvi A., Caruso M., et al. Transitory subclinical and permanent hypothyroidism in the course of subacute thyroiditis (de Quervain). Acta Endocrinol 106 (1984) 67-70
25. Nikolai T.F., Coombs G.J., McKenzie A.K., et al. Lymphocytic thyroiditis with spontaneously resolving hyperthyroidism (silent thyroiditis) and subacute thyroiditis: long-term follow-up. Arch Intern Med 142 (1982) 2281-2283
26. Lazarus J.H. Sporadic and postpartum thyroiditis. In: Braverman L.E., and Utiger R.D. (Eds). Werner's and Ingbar's the thyroid. 9th edition (2005), Lipincott, Williams, Wilkins, Philadelphia 524-535
27. Stagnaro-Green A. Postpartum thyroiditis. J Clin Endocrinol Metab 87 9 (2002) 4042-4047
28. Marqusee E., Hill J., and Mandel S. Thyroiditis after pregnancy loss. J Clin Endocrinol Metab 82 8 (1997) 2455-2457
29. Walfish P.G., Meyerson J., Papsin F., et al. Prevalence and characteristics of post-partum thyroid dysfunction: results of a survey from Toronto, Canada. J Endocrinol Invest 15 (1992) 265-272
30. Lucas A., Pizarro E., Granada M.L., et al. Postpartum thyroiditis: long-term follow-up. Thyroid 15 10 (2005) 1177-1181
31. Lazarus J.H., Ammari F., Oretti R., et al. Clinical aspects of recurrent postpartum thyroiditis. Br J Gen Pract 47 418 (1997) 305-308
32. Miller K.K., and Daniels G.H. Association between lithium use and thyrotoxicosis caused by silent thyroiditis. Clin Endocrinol (Oxf) 55 (2001) 501-508
33. Ronnblom L.E., Alm G.V., and Oberg K.E. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 115 (1991) 178-183
34. Wong V., Fu A.X., George J., et al. Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol (Oxf) 56 (2002) 793-798
35. Kennedy R.L. Amiodarone and the thyroid. Clin Chem 35 (1989) 1882-1887
36. Harjai K.J., and Licata A.A. Effects of amiodarone on thyroid function. Ann Intern Med 126 1 (1997) 63-73
37. Martino E., Safran M., Haffajee C., et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med 101 1 (1984) 28-34
38. Usui T., Shoichiro I., and Toshiaki S. Clinical and molecular features of a TSH-secreting pituitary macroadenoma. Pituitary 8 (2005) 127-134
39. Brucker-Davis F., Oldfield E.H., Skarulis M.C., et al. Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab 84 2 (1999) 476-486
40. Refetoff S. Resistance to thyroid hormone. In: Braverman L.E., and Utiger R.E. (Eds). Werner's and Ingbar's the thyroid: a fundamental and clinical text. 9th edition (2005), Lipincott, Williams, and Wilkins, Philadelphia 1109-1129
41. Olateju T., and Vanderpump M. Thyroid hormone resistance. Ann Clin Biochem 43 (2006) 431-440
42. Arevalo G. Prevalence of familial dysalbuminemic hyperthyroxinemia in serum samples received for thyroid testing. Clin Chem 37 8 (1991) 1430-1431
43. Jensen I.W., and Faber J. Familial dysalbuminemic hyperthyroxinemia. Acta Med Scand 221 (1987) 469-473
44. Stockigt S.A., Dyer S.A., Mohr V.S., et al. Specific methods to identify plasma binding abnormalities in euthyroid hyperthyroxinemia. J Clin Endocrinol Metab 62 (1986) 230-233
45. Hedberg C.W., Fishbein D.B., Janssen R.S., et al. An outbreak of thyrotoxicosis caused by the consumption of bovine thyroid gland in ground beef. N Engl J Med 316 (1987) 993-998
46. Shakir K.M., Michaels R.D., and Hays J.H. The use of bile acid sequestrants to lower serum thyroid hormones in iatrogenic hyperthyroidism. Ann Intern Med 118 2 (1993) 112-113
47. Ayhan A., Yanik F., Tuncer R., et al. Struma ovarii. Int J Gynecol Obstet 42 2 (1993) 143-146
48. Grandet P.J., and Remi M.H. Struma ovarii with hyperthyroidism. Clin Nucl Med 25 10 (2000) 763-765
49. Dardik R.B., Dardik M., Westra W., et al. Malignant struma ovarii: two case reports and a review of the literature. Gynecol Oncol 73 (1999) 447-451
50. Joja I., Asakawa T., Mitsumori A., et al. I-123 uptake in nonfunctional struma ovarii. Clin Nucl Med 23 (1998) 10-12
51. Nahn P.A., Robinson E., and Strassman M. Conservative therapy for malignant struma ovarii: a case report. J Reprod Med 47 (2002) 943-945
52. Leiter L., Sieldin S.M., and Marinelli L.D. Adenocarcinoma of the thyroid with hyperthyroidism and functional metastases. J Clin Endocrinol 6 (1946) 247-251
53. Burman K.D. Special presentations of thyroid cancer in pregnancy, renal failure, thyrotoxicosis, and struma ovarii. In: Wartofsky L., and Van Nostrand D. (Eds). Thyroid cancer: a comprehensive guide to clinical management (2006), Humana Press, Totowa (NJ) 387-392
54. Pearce E.N. Thyrotoxicosis of extrathyroid origin. In: Braverman L.E., and Utiger R.D. (Eds). Werner's and Ingbar's the thyroid. 9th edition (2005), Lippincott, Williams, Wilkins, Philadelphia 548-551
55. Wartofsky L. Thyrotoxic storm. In: Braverman L.E., and Utiger R.D. (Eds). Werner's and Ingbar's the thyroid. 9th edition (2005), Lipincott, Williams & Wilkins, Philadelphia 660-664 652-7
56. MacCrimmon D.J., Wallace J., Goldberg W.M., et al. Emotional disturbance and cognitive deficits in hyperthyroidism. Psychosom Med 41 4 (1979) 331-340
57. Ridgway E.C., Longcope C., and Maloof F. Metabolic clearance and blood production rates of estradiol in hyperthyroidism. J Clin Endocrinol Metab 41 3 (1975) 491-497
58. Ridgway E.C., Maloof F., and Longcope C. Androgen and oestrogen dynamics in hyperthyroidism. J Endocrinol 95 (1982) 105-115
59. Ojamaa K., Klemperer J.D., and Klein I. Acute effects of thyroid hormone on vascular smooth muscle. Thyroid 6 5 (1996) 505-512
60. Klein I., and Ojama K. Thyroid hormone and the cardiovascular system. N Engl J Med 344 7 (2001) 501-508
61. Klein I., and Ojamaa K. Thyrotoxicosis and the heart. Endocrinol Metab Clin North Am 27 1 (1998) 51-61
62. Ladenson P. Diagnosis of thyrotoxicosis. In: Braverman L.E., and Utiger R.D. (Eds). Werner's and Ingbar's the thyroid. 9th edition (2005), Lipincott, Williams & Wilkins, Philadelphia 660-664
63. Baloch Z., Caryon P., Conte-Devolx B., et al. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 13 1 (2003) 3-126
64. Pimental L., and Hansen K. Thyroid disease in the emergency department: a clinical and laboratory review. J Emerg Med 28 (2005) 201-209
65. Costagliola S., Morgenthaler N.G., Hoermann R., et al. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. J Clin Endocrinol Metab 84 1 (1999) 90-97
66. Quadbeck B., Hoermann R., Hahn S., et al. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment. Horm Metab Res 37 (2005) 745-750
67. Schott M., Minich W.B., Willenberg H.S., et al. Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease. Horm Metab Res 37 (2005) 741-744
68. Hidaka Y., Tamaki H., Iwatani Y., et al. Prediction of post-partum Graves' thyrotoxicosis by measurement of thyroid stimulating antibody in early pregnancy. Clin Endocrinol (Oxf) 41 (1994) 15-20
69. Tamaki H., Amino N., Aozasa M., et al. Universal predictive criteria for neonatal overt thyrotoxicosis requiring treatment. Am J Perinatol 5 2 (1988) 152-158
70. Mortimer R.H., Tyack S.A., Galligan J.P., et al. Graves' disease in pregnancy: TSH receptor binding inhibiting immunoglobulins and maternal and neonatal thyroid function. Clin Endocrinol (Oxf) 32 2 (1990) 141-152
71. Caplan R.H., Pagliara A.S., and Wickis G. Thyroxine toxicosis: a common variant of hyperthyroidism. JAMA 244 (1980) 1934-1938
72. Amino N., Yabu Y., Miyai K., et al. Serum ratio of triiodothyronine to thyroxine, and thyroxine-binding globulin and calcitonin concentrations in Graves' disease and destruction-induced thyrotoxicosis. J Clin Endocrinol Metab 53 (1981) 113-116
73. Yanagisawa T., Sato K., and Takano K. Rapid differential diagnosis of Graves' disease and painless thyroiditis using T3/T4 ratio, TSH, and total alkaline phosphatase activity. Endocr J 52 1 (2005) 29-36
74. Burman K.D., Monchik J.M., Earll J.M., et al. Ionized and total serum calcium and parathyroid hormone in hyperthyroidism. Ann Intern Med 84 (1976) 668-671
75. Sarlis N.J., and Gourgiotis L. Thyroid emergencies. Rev Endocr Metab Disord 4 (2003) 129-136
76. Britto J.M., Fenton A.J., Nicholson G.C., et al. Osteoclasts mediate thyroid hormone stimulation of osteoclastic bone resorption. Endocrinology 134 (1994) 169-176
77. Intenzo C.M., and dePapp A.E. Scintigraphic manifestations of thyrotoxicosis. Radiographics 23 4 (2003) 857-869
78. Meier D.A., and Kaplan M.M. Radioactive iodine uptake and thyroid scintiscanning. Endocrinol Metab Clin North Am 30 2 (2001) 291-313
79. Cakir M. Marine-Lenhart syndrome. J Natl Med Assoc 97 7 (2005) 1036-1038
80. Cavalieri R.R. In vivo isotopic tests and imaging. In: Braverman L.E., and Utiger R. (Eds). Werner's and Ingbar's the thyroid. 6th edition (1991), Lipincott-Ranen, Philadelphia 437-445
81. Ryu U.Y., Vaidya P.V., Schneider A.B., et al. Thyroid imaging agents: a comparison of I-123 and Tc-99m pertechnetate. Radiology 148 (1983) 819-822
82. Kurita S., Sakurai M., and Kita Y. Measurement of thyroid blood flow area is useful for diagnosing the cause of thyrotoxicosis. Thyroid 15 11 (2005) 1249-1252
83. Bogazzi F, Bartalena L, Brogiani S. Color flow Doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis. Thyroid 1997;7:541-5.
84. Astwood E. Chemotherapy of hyperthyroidism. Harvey Lect 40 (1945) 195-235
85. Cooper D. Treatment of thyrotoxicosis. In: Braverman L.E., and Utiger R.D. (Eds). Werner's and Ingbar's the thyroid. 9th edition (2005), Lipincott, Williams & Wilkins, Philadelphia 665-694
86. Sonnet E., Massart C., Gibassier J., et al. Longitudinal study of soluble intracellular adhesion molecule-1 (ICAM-1) in sera of patients with Graves' disease. J Endocrinol Invest 22 (1999) 430-435
87. Tsatsoulis A., Vlachoyiannopoulos P.G., Dalekos G.N., et al. Increased serum interleukin-1 beta during treatment of hyperthyroidism with antithyroid drugs. Eur J Clin Invest 25 (1995) 654-658
88. McGregor A.M., Peterson M.M., Mclachlan S.M., et al. Carbimazole and the autoimmune response in Graves' disease. N Engl J Med 303 (1980) 302-307
89. Zantut-Wittman D.E., Tambascia M.A., da Silva Trevisan M.A., et al. Antithyroid drugs inhibit in vivo HLA-DR expression in thyroid follicular cells in Graves' disease. Thyroid 11 (2001) 575-580
90. Tajiri J., and Noguchi S. Antithyroid drug-induced agranulocytosis: special reference to normal white blood cell count agranulocytosis. Thyroid 14 (2004) 459-462
91. Romaldini J.H., Bromberg N., and Reis L.C. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism. J Clin Endocrinol Metab 57 3 (1983) 563-570
92. Pujol P., Osman A., Jaffiol C., et al. TSH suppression combined with carbimazole for Graves' disease: effect on remission and relapse rate. Clin Endocrinol (Oxf) 48 5 (1998) 635-640
93. Pfeilschifter J., and Ziegler R. Suppression of serum thyrotropin with thyroxine in patients with Graves' disease: effects on recurrence of hyperthyroidism and thyroid volume. Eur J Endocrinol 136 1 (1997) 81-86
94. McIver B., Rae P., Toft A., et al. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. N Engl J of Med 334 4 (1996) 220-224
95. Shiroozu A., Okamura K., Yashizumi T., et al. Treatment of hyperthyroidism with a single daily dose of methimazole. J Clin Endocrinol Metab 63 1 (1986) 125-128
96. Nicholas W.C., Fischer R.G., Stevenson R.A., et al. Single daily dose of methimazole compared to every 8 hours propylthiouracil in the treatment of hyperthyroidism. South Med J 88 9 (1995) 973-976
97. Bouma D.J., and Kammer H. Single daily dose methimazole treatment of hyperthyroidism. West J Med 132 (1980) 13-15
98. He C.T., Hsieh A.T., Kuo S.W., et al. Comparison of single daily dose methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism. Clin Endocrinol (Oxf) 60 (2004) 676-681
99. Nagasaka A., and Hikada H. Effect of antithyroid agents 6-propyl-2-thiouracil and 1-methyl-2-mercaptoimidazole on human thyroid iodide peroxidase. J Clin Endocrinol Metab 43 (1976) 152-158
100. Jansson R., Dahlberg P.A., Lindstrom B., et al. Intrathyroidal concentrations of methimazole in patients with Graves' disease. J Clin Endocrinol Metab 57 (1983) 129-132
101. Okamura K., Ikenoue H., Shiroozu A., et al. Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab 65 (1987) 719-723
102. Walter R.M., and Bartle W.R. Rectal administration of propylthiouracil in the treatment of Graves' disease. Am J Med 88 (1990) 69-70
103. Nabil N., Miner D.J., and Amatruda J.M. Methimazole: an alternative route of administration. J Clin Endocrinol Metab 54 1 (1982) 180-181
104. Yeung S., Go R., Balasubramanyam A., et al. Rectal administration of iodide and propylthiouracil in the treatment of thyroid storm. Thyroid 5 5 (1995) 403-405
105. Jongjaroenprasert W., Akarawut W., Chantasart D., et al. Rectal administration of propylthiouracil in hyperthyroid patients: comparison of suspension enema and suppository form. Thyroid 12 7 (2002) 627-631
106. Okamura Y., Shigemusa C., and Tatsuhara T. Pharmacokinetics of methimazole in normal subjects and hyperthyroid patients. Endocrinol Jpn 33 (1986) 605-615
107. Hodak S.P., Huang C., Clarke D., et al. Intravenous methimazole in the treatment of refractory hyperthyroidism. Thyroid 16 7 (2006) 691-695
108. Werner M.C., Romaldini J.H., Farah C.S., et al. Adverse effects related to thionamide drugs and their dose regimen. Am J Med Sci 297 (1989) 216-219
109. Pearce S.H. Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK. Clin Endocrinol (Oxf) 61 (2004) 589-594
110. Tajiri J., and Noguchi S. Antithyroid drug-induced agranulocytosis: how has granulocyte colony-stimulating factor changed therapy?. Thyroid 15 3 (2005) 292-297
111. Cooper D.S., Goldminz D., Ridgway E.C., et al. Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med 98 (1983) 26-29
112. Cooper D.S. Antithyroid drugs for the treatment of hyperthyroidism caused by Graves' disease. Endocrinol Metab Clin North Am 27 (1998) 225-247
113. Sheng W.H., Hung C.C., Chen Y.C., et al. Antithyroid drug-induced agranulocytosis complicated by life-threatening infections. QJM 92 (1999) 455-461
114. Cooper D. Antithyroid drugs. N Engl J Med 352 (2005) 905-917
115. Hughes G. Management of thyrotoxicosis with a beta-adrenergic blocking agent. Br J Clin Pract 20 (1966) 579-581
116. Langley R.W., and Burch H.B. Perioperative management of the thyrotoxic patient. Endocrinol Metab Clin North Am 32 (2003) 519-534
117. Taurog A. Hormone synthesis: thyroid iodine metabolism. In: Braverman L.E., and Utiger R.D. (Eds). Werner's and Ingbar's the thyroid. 6th edition (1991), Lipincott, Williams, Wilkins, Philadelphia 51-97
118. Goldberg P.A., and Inzucchi S.E. Critical issues in endocrinology. Clin Chest Med 24 (2003) 583-606
119. Panzer C., Beazley R., and Braverman L. Rapid preoperative preparation for severe hyperthyroid Graves' disease. J Clin Endocrinol Metab 89 (2004) 2142-2144
120. Boehm T.M., Burman K.D., Barnes S., et al. Lithium and iodine combination therapy for thyrotoxicosis. Acta Endocrinol (Copenh) 94 (1980) 174-183
121. Spaulding S.W., Burrow G.N., Bermudez F., et al. The inhibitory effect of lithium on thyroid hormone release in both euthyroid and thyrotoxic patients. J Clin Endocrinol Metab 35 6 (1972) 905-911
122. Solomon B.L., Wartofsky L., and Burman K.D. Adjunctive cholestyramine therapy for thyrotoxicosis. Clin Endocrinol (Oxf) 38 (1993) 39-43
123. Mercado M., Mendoza-Zubieta V., Bautista-Osorio R., et al. Treatment of hyperthyroidism with a combination of methimazole and cholestyramine. J Clin Endocrinol Metab 81 9 (1996) 3191-3193
124. Tsai W.C., Pei D., Wang T., et al. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism. Clin Endocrinol (Oxf) 62 5 (2005) 521-524
125. Holm L.E., Hall P., Lundell G., et al. Cancer risk after iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst 83 15 (1991) 1072-1076
126. Franklyn J.A., Maissonneuve P., Sheppard M., et al. Cancer incidence and mortality after radioactive iodine treatment for hyperthyroidism: a population-based cohort study. Lancet 353 (1999) 2111-2115
127. Sridama V., McCormick M., Kaplan E.L., et al. Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease. N Engl J Med 311 7 (1984) 426-432
128. Nordyke R.A., and Gilbert Jr. F.I. Optimal iodine-131 dose for eliminating hyperthyroidism in Graves' disease. J Nucl Med 32 3 (1991) 411-416
129. Cevallos J.L., Hagen G.A., Maloof F., et al. Low-dosage 131-I therapy of thyrotoxicosis (diffuse goiters). A five-year follow-up study. N Engl J Med 290 3 (1974) 141-143
130. Burman K. Hyperthyroidism. In: Rakel R., and Bope E. (Eds). Conn's current therapy (2006), Saunders, Philadelphia 806-811
131. McDermott M.T., Kidd G.S., Dodson L.E., et al. Radioactive iodine-induced thyroid storm. Case report and literature review. Am J Med 75 2 (1983) 353-359
132. Bonnema S.J., Bennedbaek F.N., Veje A., et al. Propylthiouracil before I-131 therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial. J Clin Endocrinol Metab 89 9 (2004) 4439-4444
133. Santos R.B., Romaldini J.H., and Ward L.S. Propylthiouracil reduces the effectiveness of radioactive iodine treatment in hyperthyroid patients with Graves' disease. Thyroid 14 (2004) 525-530
134. Andrade V.A., Gross J.L., and Maia A.L. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study. J Clin Endocrinol Metab 86 8 (2001) 3488-3493
135. Bonnema S.J., Bennedbaek F.N., Veje A., et al. Continuous methimazole therapy and its effect on the cure rate of hyperthyroidism using radioactive iodine: an evaluation by a randomized trial. J Clin Endocrinol Metab 91 8 (2006) 2946-2951
136. Sabri O., Zimny M., Buell U., et al. Success rate of radioactive iodine therapy in Graves' disease: the influence of thyrostatic medication. J Clin Endocrinol Metab 84 4 (1999) 1229-1233
137. Vitti P., Rago T., and Chiovato L. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 7 (1997) 369-375
138. Hedley A.J., Young R.E., Jones S.J., et al. Antithyroid drugs in the treatment of hyperthyroidism of Graves' disease: long-term follow-up of 434 patients. Clin Endocrinol (Oxf) 31 (1989) 209-218
139. Bartalena L., Pinchera A., and Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 21 2 (2000) 168-199
140. Kahaly G.J., Pitz S., Dittmar M., et al. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab 90 9 (2005) 5234-5240
141. Bartalena L., Marcocci C., and Pincher A. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 338 2 (1998) 73-78
142. Tallstedt L., Lundell G., and Taube A. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med 326 26 (1992) 1733-1738
143. Hegedius L., Brix T.H., and Vestergaard P. Relationship between cigarette smoking and Graves' ophthalmopathy. J Endocrinol Invest 27 3 (2004) 265-271
144. Bartalena L., Marcocci C., Manetti L., et al. Cigarette smoking and treatment outcomes in Graves' ophthalmopathy. Ann Intern Med 129 (1998) 632-635
145. Siegel R.D., and Lee S.L. Toxic nodular goiter: toxic adenoma and toxic multinodular goiter. Endocrinol Metab Clin North Am 27 1 (1998) 151-168
146. Bartalena L., Brogioni S., Grasso L., et al. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. J Clin Endocrinol Metab 81 8 (1996) 2930-2933
147. Martino E., Aghini-Lombardi F., and Mariotti S. Treatment of amiodarone associated thyrotoxicosis by simultaneous administration of potassium perchlorate and methimazole. J Endocrinol Invest 9 (1986) 201-207
148. Soldin O.P., Braverman L.E., and Lamm S.H. Perchlorate clinical pharmacology and human health: a review. Ther Drug Monit 23 (2001) 316-331
149. Erdogan M.F., Gulec S., Tutar E., et al. A stepwise approach to the treatment of amiodarone-induced thyrotoxicosis. Thyroid 13 2 (2003) 205-209
150. Roti E., Minelli R., Braverman L.E., et al. Thyrotoxicosis followed by hypothyroidism in patients treated with amiodarone: a possible consequence of a destructive process of the thyroid. Arch Intern Med 153 (1993) 886-892
151. Davis L.E., Lucas M.J., Hankins G.D., et al. Thyrotoxicosis complicating pregnancy. Am J Obstet Gynecol 160 (1989) 63-70
152. LeBeau S.O., and Mandel S.J. Thyroid disorders during pregnancy. Endocrinol Metab Clin North Am 35 (2006) 117-136
153. Davies T.F., Ando T., Lin R.Y., et al. Thyrotropin receptor-associated diseases: from adenomata to Graves' disease. J Clin Invest 115 8 (2005) 1972-1983
154. Rodien P., Bremont C., Duprez L., et al. Familial gestational hyperthyroidism caused by a mutant thyrotropin receptor hypersensitive to human chorionic gonadotropin. N Engl J Med 339 25 (1998) 1823-1826
155. Goodwin T.M., Montoro M., Hershman J.M., et al. The role of chorionic gonadotropin in transient hyperthyroidism of hyperemesis gravidarum. J Clin Endocrinol Metab 75 (1992) 1333-1337
156. Grossman M., Weintraub B.D., and Szudlinski M.W. Novel insights into the molecular mechanisms of human thyrotropin action: structural, physiological, and therapeutic implications for the glycoprotein hormone family. Endocr Rev 18 (1997) 476-501
157. Bach-Huynh T.G., and Jonklaas J. Thyroid medications during pregnancy. Ther Drug Monit 28 3 (2006) 431-441
158. Burrow G.N. Thyroid function and hyperfunction during gestation. Endocr Rev 14 (1993) 194-202
159. Masiukiewicz U.S., and Burrow G.N. Hyperthyroidism in pregnancy: diagnosis and treatment. Thyroid 9 (1999) 647-652
160. Marchant B., Brownie B.E.W., Hart D.M., et al. The placental transfer of propylthiouracil, methimazole, and carbimazole. J Clin Endocrinol Metab 45 (1977) 1187-1193
161. Kalb R.E., and Grossman M.E. The association of aplasia cutis congenita with therapy of maternal thyroid disease. Pediatr Dermatol 3 (1986) 327-330
162. Van Dijke C.P., Heydendael R.J., and de Kleine M.J. Methimazole, carbimazole, and congenital skin defects. Ann Intern Med 106 (1987) 60-61
163. Mortimer R., Connell G., Addison R., et al. Methimazole and propylthiouracil equally cross the perfused human term placental lobule. J Clin Endocrinol Metab 82 (1997) 3099-3102
164. Momotani N., Noh J., Oyanagi H., et al. Antithyroid drug therapy for Graves' disease during pregnancy: optimal regimen for fetal thyroid status. N Engl J Med 315 (1986) 24-28
165. Mestman J.H. Hyperthyroidism in pregnancy. Best Pract Res Clin Endocrinol Metab 18 2 (2004) 267-288
166. Brodsky J.B., Cohen E.N., Brown Jr. B.W., et al. Surgery during pregnancy and fetal outcome. Am J Obstet Gynecol 138 8 (1980) 1165-1167
167. Fisher D.A. Fetal thyroid function: diagnosis and management of fetal thyroid disorders. Clin Obstet Gynecol 40 (1997) 16-31
168. Davidson K.M., Richards D.S., Schatz D.A., et al. Successful in utero treatment of fetal goiter and hypothyroidism. N Engl J Med 324 (1991) 543-546
169. Van Loon A.J., Derksen J., Bos A.F., et al. In utero diagnosis and treatment of fetal goitrous hypothyroidism, caused by maternal use of propylthiouracil. Prenat Diagn 15 (1995) 599-604